The FDA’s corruption knows no limit and agency advisors recommended authorizing the Novavax COVID-19 shot during an advisory committee meeting on Tuesday.
The committee ignored the agency’s previous assessment of the non-mRNA COVID-19 shot.
The FDA released a report on Friday regarding the risk of myocarditis from the Novavax jab.
FDA Issues Myocarditis Warning for Non-mRNA Novavax COVID-19 Shot
BREAKING: COVID-19 Vaccine Efficacy (VE) against Any Death is -9%, while VE against COVID-19 is 90%, according to latest @FDA meeting with @Novavax!#Covid #Covid19 #Corona #Coronavirus #Vaccine pic.twitter.com/VwsOBdD9ST
— Ben (@USMortality) June 7, 2022
FDA panel recommends Novavax COVID vaccine be the fourth allowed for use in US https://t.co/9H0S4eWOhv
— USA TODAY (@USATODAY) June 7, 2022
USA Today reported:
A federal advisory committee recommended Tuesday that a fourth COVID-19 vaccine be authorized for use in the USA, this one from Novavax, a company based in Gaithersburg, Maryland.
The vaccine, which was supported by $1.8 billion in taxpayer funding, relies on a more traditional approach than the vaccines from Moderna and Pfizer-BioNTech, which have been used by more than three-quarters of Americans.
A third vaccine, from Johnson & Johnson, was used in more than 16 million people, but has been recommended as a second choice because of a side effect that's extremely rare but potentially lethal.
According to polling data, 73% of Americans want more vaccine choices.
Dr. Peter Marks, head of the Food and Drug Administration's vaccine review division, opened Tuesday's meeting by saying that because of vaccine hesitancy – which has left about 23% of the public unvaccinated – the government should do everything within its power to offer more options.
Before the vaccine can become available, the head of the FDA must agree with the advisory panel that the benefits of Novavax's vaccine outweigh its risks. Then, a Centers for Disease Control and Prevention panel and the CDC's director must sign off on the vaccine. That process is likely to take a few weeks at least.
Novavax said it has millions of doses available and ready to be shipped once it receives authorization.
The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.
In the FDA documents, the agency said that multiple events of myocarditis/pericarditis were reported after the administration of the Novavax COVID-19 shot.
Thus, raising concern about a possible risk of heart inflammation from the shot.
Similar to the Pfizer, Moderna, and Johnson & Johnson shots, the Novavax jab has an abysmal safety profile with potentially catastrophic side effects.
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!